Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 7:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 16,842 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Complication Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Pharmacokinetics, Safety, and Tolerability of Intravenous ETX2514 and Sulbactam Administered Concurrently to Subjects With Various Degrees of Renal Impairment and Healthy Matched Control Subjects

NCT03310463
View directory record Official record
Conditions
Acinetobacter Baumannii Infection
Interventions
ETX2514SUL
Drug
Lead sponsor
Entasis Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
3
States / cities
Lakewood, Colorado • Miami, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 25, 2026, 7:17 PM EDT
Active, not recruiting No phase listed Observational

Identifying Genetic Characteristics That Increase Risk of Primary Graft Dysfunction Following Lung Transplantation

NCT00457847
View directory record Official record
Conditions
Primary Graft Dysfunction, Lung Transplantation
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
15 Years to 65 Years
Enrollment
1,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 25, 2026, 7:17 PM EDT
Completed No phase listed Observational

Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus

NCT00004363
View directory record Official record
Conditions
Diabetes Insipidus, Diabetes Insipidus, Neurohypophyseal
Interventions
chlorpropamide, desmopressin
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
6 Months to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 25, 2026, 7:17 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Bilateral Continuous Erector Spinae Blocks for Post-Sternotomy Pain Management: A Pilot Study

NCT03936387
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Ropivacaine
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
3 Years to 21 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Oct 25, 2026, 7:17 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease

NCT01559363
View directory record Official record
Conditions
Polycystic Kidney, Autosomal Dominant
Interventions
Tesevatinib
Drug
Lead sponsor
Kadmon, a Sanofi Company
Industry
Eligibility
18 Years to 62 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
11
States / cities
Los Angeles, California • Denver, Colorado • Kansas City, Kansas + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 25, 2026, 7:17 PM EDT
Completed Phase 2 Interventional Results available

Ascertain the Optimal Starting Dose of Mircera Given Subcutaneously for Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis or Not Yet on Dialysis.

NCT03552393
View directory record Official record
Conditions
Anemia, Renal Insufficiency, Chronic
Interventions
Mircera
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
3 Months to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
7
States / cities
Birmingham, Alabama • Loma Linda, California • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2022 · Synced Oct 25, 2026, 7:17 PM EDT
Terminated Phase 2 Interventional Results available

A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer

NCT03165721
View directory record Official record
Conditions
Paraganglioma, Gastrointestinal Stromal Tumors, Carcinoma, Renal Cell, Renal Neoplasms, Pheochromocytoma
Interventions
SGI-110 (guadecitabine)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 99 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 25, 2026, 7:17 PM EDT
Completed Phase 3 Interventional Results available

A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)

NCT02684006
View directory record Official record
Conditions
Renal Cell Cancer
Interventions
Avelumab (MSB0010718C), Axitinib (AG-013736), Sunitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
886 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
93
States / cities
Daphne, Alabama • Mobile, Alabama • Beverly Hills, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Oct 25, 2026, 7:17 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation of Oral Lipid Ingestion in Relation to Ovarian Androgen Secretion in Polycystic Ovary Syndrome (PCOS)

NCT01489319
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Salsalate
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 25, 2026, 7:17 PM EDT
Not listed Not applicable Interventional

Use of Pedometer Following Radical Cystectomy

NCT04305730
View directory record Official record
Conditions
Bladder Cancer, Ileus, Narcotic Use
Interventions
Use of a pedometer following surgery, Standard of care
Behavioral
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Oct 25, 2026, 7:17 PM EDT
Suspended Not applicable Interventional

SCD for CRS in Congestive Heart Failure (CHF) (No Left Ventricular Assist Device)

NCT04589065
View directory record Official record
Conditions
Heart Failure, Chronic Systolic Heart Failure, Renal Failure, Cardiorenal Syndrome
Interventions
Selective Cytopheretic Device
Device
Lead sponsor
Lenar Yessayan
Other
Eligibility
21 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 27, 2024 · Synced Oct 25, 2026, 7:17 PM EDT
Active, not recruiting Not applicable Interventional

Postoperative VR for Recovery After Bariatric Surgery

NCT04754165
View directory record Official record
Conditions
Bariatric Surgery Candidate, Postoperative Pain, Postoperative Complications
Interventions
Virtual Reality Immersive Relaxation
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 25, 2026, 7:17 PM EDT
Active, not recruiting Phase 2 Interventional

Renal Mechanism of SGLT2 Inhibition

NCT05507892
View directory record Official record
Conditions
Type 2 Diabetes, Diabetic Kidney Disease
Interventions
canagliflozin, Aminohippurate Sodium Inj 20%
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Aurora, Colorado • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 25, 2026, 7:17 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Imatinib Mesylate to Treat Nephrogenic Systemic Fibrosis

NCT00677092
View directory record Official record
Conditions
Nephrogenic Systemic Fibrosis
Interventions
Imatinib mesylate
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 19, 2017 · Synced Oct 25, 2026, 7:17 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer

NCT01200992
View directory record Official record
Conditions
Bladder Neoplasm, Neoplasm Recurrence, Local, Transitional Cell, Carcinoma, Carcinoma in Situ, Mycobacterium
Interventions
EN3348, Mitomycin C
Biological
Lead sponsor
Bioniche Life Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
56
States / cities
Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2017 · Synced Oct 25, 2026, 7:17 PM EDT
Completed Phase 3 Interventional Results available

The Bladder Instillation Comparison Study

NCT02695771
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
Mitomycin C, Gemcitabine
Drug
Lead sponsor
Corewell Health West
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
3
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 21, 2023 · Synced Oct 25, 2026, 7:17 PM EDT
Completed Phase 2 Interventional

Port Will be Flushed Every 3 Months Instead of Every 4-6 Wks, as Recommended by Port Manufacturer.

NCT01047644
View directory record Official record
Conditions
Complication of Catheter
Interventions
Reduced port-flush schedule
Other
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 85 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Oct 25, 2026, 7:17 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Urinary Catheter Self-Discontinuation After Urogynecology Surgery

NCT05860634
View directory record Official record
Conditions
Urinary Retention, Pelvic Organ Prolapse, Stress Urinary Incontinence, Catheter Related Complication
Interventions
Catheter self-discontinuation
Procedure
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older · Female only
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
4
States / cities
Austin, Texas • Kyle, Texas • Round Rock, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 25, 2026, 7:17 PM EDT
Active, not recruiting Phase 2 Interventional

RIC-NEC Randomized Controlled Trial

NCT05279664
View directory record Official record
Conditions
Necrotizing Enterocolitis
Interventions
Remote ischemic conditioning (RIC) + Standard of Care for NEC, Standard of Care for NEC
Other
Lead sponsor
The Hospital for Sick Children
Other
Eligibility
0 Weeks and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 25, 2026, 7:17 PM EDT
Terminated Not applicable Interventional Results available

A Pragmatic Approach to CKD Patient Education

NCT05138419
View directory record Official record
Conditions
Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Chronic Kidney Disease Stage 5, Patient Engagement
Interventions
CKD "What You Need To Know" Workbook System, CKD Action Plan, CKD Web-based Resource List, Food Label reading exercise
Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 105 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 25, 2026, 7:17 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Atorvastatin for Orthopedic Surgery Patients

NCT02197065
View directory record Official record
Conditions
Hip Fracture, Myocardial Ischemia, Inflammation
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
65 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 25, 2026, 7:17 PM EDT
Completed Phase 2 Interventional Results available

Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

NCT00096200
View directory record Official record
Conditions
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Carboplatin, Paclitaxel, Sorafenib Tosylate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
5
States / cities
Tampa, Florida • Cleveland, Ohio • Mentor, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Oct 25, 2026, 7:17 PM EDT
Active, not recruiting Not applicable Interventional

Pelvic Floor Physical Therapy to Reduce Stress Urinary Incontinence After Holmium Laser Enucleation of the Prostate

NCT06209307
View directory record Official record
Conditions
Prostatic Hyperplasia, Stress Urinary Incontinence
Interventions
Pelvic floor physical therapy
Behavioral
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Male only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 25, 2026, 7:17 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

BioThrax® (Anthrax) Vaccine in Pregnancy Registry

NCT01653392
View directory record Official record
Conditions
Pregnancy Complications, Pregnancy Outcome, Congenital Abnormalities
Interventions
Observational Intervention
Biological
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
Female only
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2020
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 25, 2026, 7:17 PM EDT